Dichloromethylene diphosphonate action in hematologic and other malignancies

Area of Science:

• Oncology
• Pharmacology
• Nephrology

Background:

• Hypercalcemia and hypercalciuria are common complications of multiple myeloma and other malignancies, driven by increased bone resorption.
• Existing treatments for malignancy-related hypercalcemia have limitations, necessitating exploration of novel therapeutic agents.

Purpose of the Study:

• To evaluate the efficacy of oral and intravenous dichloromethylene diphosphonate (Cl2MDP) in managing hypercalcemia and hypercalciuria.
• To assess the impact of Cl2MDP on bone resorption markers and bone pain in cancer patients.

Main Methods:

• A double-blind, placebo-controlled trial involving 14 patients with refractory multiple myeloma receiving oral Cl2MDP (1600 mg twice daily) for 16 weeks.
• Administration of intravenous Cl2MDP (2.5-5 mg/kg daily for up to 7 days) in 12 patients with hypercalcemia of malignancy.
• Monitoring of serum calcium, urinary calcium, and urinary hydroxyproline levels.

Main Results:

• Oral Cl2MDP significantly reduced urinary calcium in 11 of 12 patients (P < 0.001), with 9 achieving normal levels.
• Urinary hydroxyproline and bone pain decreased significantly in responders treated with oral Cl2MDP.
• Intravenous Cl2MDP normalized serum calcium within a mean of four days in patients with hematologic malignancies and solid tumors.

Conclusions:

• Dichloromethylene diphosphonate (Cl2MDP) is an effective treatment for hypercalcemia and hypercalciuria associated with multiple myeloma and bone metastases.
• Both oral and intravenous administration of Cl2MDP demonstrate significant efficacy in reducing markers of bone resorption and improving clinical symptoms.
• Cl2MDP represents a promising therapeutic option for managing bone complications in cancer patients.